紫杉醇联合奈达铂治疗晚期非小细胞肺癌

A clinical study of nedaplatin combined with paclitaxel in treatment for advanced non-small cell lung cancer

目的评价紫杉醇联合奈达铂治疗晚期非小细胞肺癌的疗效和毒副反应。方法 33例经病理确诊的晚期非小细胞肺癌患者,初治或复治,ⅢB期(伴胸腔积液)或Ⅳ期,重要脏器功能正常,PS评分0～2分的患者入组。紫杉醇175mg/m2,第1天,奈达铂80mg/m2,第1天,每21d为一疗程。结果本组33例患者均已完成至少2个疗程化疗。初治组和复治组的有效率分别为41.1%、31.3%,中位生存期分别为425d和343d。发生白细胞减少和血小板减少的疗程数分别占总疗程数的65.5%和19%,无治疗相关性死亡。结论紫杉醇联合奈达铂治疗晚期非小细胞肺癌,疗效确切,对顺铂耐药患者仍然有效,耐受性好。

Objective To observe the safety and efficacy of nedaplatin plus paclitaxel in treatment of advanced non-small cell lung cancer（NSCLC）.Methods Patients with NSCLC,no matter weather previously treated,either stage ⅢB with pleural effusion or stage Ⅳ,were enrolled if they had a performance status of 0~2,and had adequate organ function.The respectively doses of nedaplatin day 1 and paclitaxel days 1 were 80 mg/m^2 and 175 mg/m^2,repeated every 21 days.Results 33 patients got the above regimen for at least 2 cycles,of them,17（The initial treatment group）were untreated before and 16（Retreatment group）had previously received chemotherapy.The overall response rate were 41.1% vs 31.3%,and the median survival time were 425 days vs 343 days in The initial treatment group and Retreatment group respectively.The overall rates of neutropenia and thrombocytopenia were 65.5% and 19% in all 33 courses,calculated by course.There were no treatment-related deaths.Conclusion Nedaplatin combined with paclitaxel is an effective and safe treatment regimen for advanced NSCLC patients,even in those resistant to cisplatin.